Antibody Drug Conjugates are the fastest growing class of oncology therapeutics. These are monoclonal antibody based therapies which have achieved great success in the field of cancer treatment, primarily when used with cytotoxic drugs. ADC is a class of therapeutics which harnesses the antigen-selectivity of monoclonal antibodies to deliver the highly potent cytotoxic drugs to antigen expressing tumor cells. The use of monoclonal antibody directed delivery confers a therapeutic index to highly potent cytotoxic drugs, increasing both the efficacy and safety of therapy. Such novel anti-cancer drugs are being used these days to target cancers, while minimizing the exposure of healthy tissue. The recent approval of four ADCs in the global market and a strong pipeline of such drugs, highlight the potential for new therapeutic innovations in this industry.
According to the RNCOS report entitled "Global Antibody Drug Conjugate Drug Sales, Pipeline Analysis (By Phase, Linker, Technology, and Indication) and Market Forecast to 2023", the Global Antibody Drug Conjugates Market is anticipated to witness a double digit growth during 2017-2023. The report provides information about the current and future market scenario of the Global ADCs Market. The report also highlights the major drivers, such as increasing incidences of cancer and advances in linking technologies, for the Global Antibody Drug Conjugates Market. Furthermore, the report also gives information related to the commercially available ADCs such as ADCETRIS, Kadcyla, Mylotarg and Besponsa.
Moreover, few hindrances, such as high cost of production cost, lack of experienced manufacturers and regulatory challenges, which are slowing down the growth of the Global ADCs Market, have also been mentioned in the report. In addition, the report also highlights various trends and developments taking place in this market.
Furthermore, in this report, we have structured the information regarding ADCs at various stages of clinical development that are under research or in collaboration, and those individually being developed by companies. The pipeline chapter provides in depth analysis of ADCs of companies as well as research organizations by clinical phase, indications for which they are being developed, type of linker, drugs, and technology. Additionally, the study provides all-inclusive current analysis of various ADCs in advanced as well as early stages of development. Moreover, our report places an emphasis on the strategic alliances that can impact industry's growth.
The prominent players in Global Antibody Drug Conjugates Market have been discussed in the last section of the report. A brief business overview and financial information about each of these players has been provided, along with their product portfolios, product pipeline and recent developments. Overall, the research contains exhaustive information that will help clients in formulating market strategies and assessing opportunity areas in the Global Antibody Drug Conjugates Market.
Secondary Research Information is collected from a number of publicly available as well as paid databases. Public sources involve publications by different associations and governments, annual reports and statements of companies, white papers and research publications by recognized industry experts and renowned academia etc. Paid data sources include third party authentic industry databases.
Once data collection is done through secondary research, primary interviews are conducted with different stakeholders across the value chain like manufacturers, distributors, ingredient/input suppliers, end customers and other key opinion leaders of the industry. Primary research is used both to validate the data points obtained from secondary research and to fill in the data gaps after secondary research.
The market engineering phase involves analyzing the data collected, market breakdown and forecasting. Macroeconomic indicators and bottom-up and top-down approaches are used to arrive at a complete set of data points that give way to valuable qualitative and quantitative insights. Each data point is verified by the process of data triangulation to validate the numbers and arrive at close estimates.
The market engineered data is verified and validated by a number of experts, both in-house and external.
REPORT WRITING/ PRESENTATION
After the data is curated by the mentioned highly sophisticated process, the analysts begin to write the report. Garnering insights from data and forecasts, insights are drawn to visualize the entire ecosystem in a single report.
Single User License - Only one user can access this report at time, users are not allowed to take a print out of the report PDF.
Enterprise User License - This license will allow the entire company (Interface) to access the unlocked PDF version of this report without any restrictions. You can also take the print out if you wish to receive the hard copy version of this report.
Multi User License - This license will be allowing up to five users have access to the product. The report will be emailed to you. The report is sent in PDF format.
Site License - This is a site license, allowing all users within a given geographical location of your organisation access to the product. The report will be emailed to you. The report is sent in PDF format.